|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
GB9119338D0
(en)
|
1991-09-10 |
1991-10-23 |
Inst Of Animal Physiology And |
Control of gene expression
|
|
US5523226A
(en)
*
|
1993-05-14 |
1996-06-04 |
Biotechnology Research And Development Corp. |
Transgenic swine compositions and methods
|
|
US5512295A
(en)
|
1994-11-10 |
1996-04-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthetic liposomes for enhanced uptake and delivery
|
|
US6001349A
(en)
|
1995-02-22 |
1999-12-14 |
Therion Biologics Corporation |
Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7001614B2
(en)
|
1996-08-19 |
2006-02-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Liposome complexes for increased systemic delivery
|
|
US6770291B2
(en)
|
1996-08-30 |
2004-08-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Liposome complexes for increased systemic delivery
|
|
CA2722378C
(en)
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6749863B1
(en)
|
1997-11-19 |
2004-06-15 |
Georgetown University |
Targeted liposome gene delivery
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9823930D0
(en)
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
WO2002076196A1
(en)
|
2001-03-22 |
2002-10-03 |
Abbott Gmbh & Co. Kg |
Transgenic animals expressing antibodies specific for genes of interest and uses thereof
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20090042291A1
(en)
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
|
EP1575601B1
(en)
|
2002-12-16 |
2015-07-01 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Recombinant vaccine viruses expressing il-15 and methods of using the same
|
|
EP3202899B1
(en)
|
2003-01-28 |
2020-10-21 |
Cellectis |
Custom-made meganuclease and use thereof
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
US8218805B2
(en)
|
2003-10-11 |
2012-07-10 |
Charles Hornback |
Wireless speaker system for use with ceiling fans
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
AU2005247950B2
(en)
|
2004-05-27 |
2012-02-02 |
Receptor Logic, Inc. |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
|
ES2463476T3
(es)
|
2004-10-19 |
2014-05-28 |
Regeneron Pharmaceuticals, Inc. |
Método para generar un ratón homocigótico para una modificación genética
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
US20060222653A1
(en)
|
2004-11-12 |
2006-10-05 |
Xencor, Inc. |
Antibodies operably linked to selected chemoattractants
|
|
EP1858925A2
(en)
|
2005-01-12 |
2007-11-28 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
|
CN103710371B
(zh)
*
|
2005-08-03 |
2017-03-01 |
人类多克隆治疗股份有限公司 |
表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制
|
|
WO2007022520A2
(en)
|
2005-08-19 |
2007-02-22 |
Cerus Corporation |
Antibody-mediated enhancement of immune response
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
AU2007235496B2
(en)
|
2006-03-31 |
2013-11-21 |
E. R. Squibb & Sons, L.L.C. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
|
PL2602323T3
(pl)
|
2007-06-01 |
2018-06-29 |
Open Monoclonal Technology, Inc. |
Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
|
|
AU2008312444B2
(en)
|
2007-10-18 |
2014-02-06 |
Bavarian Nordic A/S |
Use of MVA to treat prostate cancer
|
|
US8225343B2
(en)
|
2008-01-11 |
2012-07-17 |
Sony Computer Entertainment America Llc |
Gesture cataloging and recognition
|
|
EP2147594B1
(en)
|
2008-06-27 |
2013-11-13 |
Merus B.V. |
Antibody producing non-human mammals
|
|
AU2009298458B2
(en)
|
2008-09-30 |
2015-10-08 |
Ablexis, Llc |
Non-human mammals for the production of chimeric antibodies
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
DK3622815T3
(da)
|
2009-07-08 |
2023-06-26 |
Kymab Ltd |
Gnavermodeller og terapeutiske molekyler
|
|
RU2425880C2
(ru)
*
|
2009-07-30 |
2011-08-10 |
Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН |
Способ получения трансгенных мышей
|
|
ES2724975T3
(es)
*
|
2009-12-10 |
2019-09-18 |
Regeneron Pharma |
Ratones que producen anticuerpos de cadena pesada
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US20130185821A1
(en)
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
SMT202600080T1
(it)
|
2010-02-08 |
2026-03-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
JP2013528357A
(ja)
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
ES2984483T3
(es)
|
2010-03-31 |
2024-10-29 |
Ablexis Llc |
Ingeniería genética de ratones para la producción de anticuerpos quiméricos
|
|
PT3034608T
(pt)
|
2010-06-22 |
2019-05-28 |
Regeneron Pharma |
Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
|
|
CN103025884B
(zh)
|
2010-07-26 |
2015-11-25 |
特里安尼公司 |
转基因动物和使用方法
|
|
SMT201700023T1
(it)
|
2010-08-02 |
2017-03-08 |
Regeneron Pharma |
Topi che producono proteine leganti vl
|
|
ME02106B
(me)
|
2011-02-25 |
2015-10-20 |
Regeneron Pharma |
Miševi sa adam6
|
|
JP5893258B2
(ja)
|
2011-03-31 |
2016-03-23 |
フェリカネットワークス株式会社 |
情報処理装置および方法、並びにプログラム
|
|
US20130018582A1
(en)
|
2011-07-13 |
2013-01-17 |
Miller Paul A |
Inertial Navigation Common Azimuth Reference Determination System and Method
|
|
HUE047278T2
(hu)
|
2011-08-05 |
2020-04-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
SG11201401181YA
(en)
|
2011-10-17 |
2014-04-28 |
Regeneron Pharma |
Restricted immunoglobulin heavy chain mice
|
|
CN107858333B
(zh)
|
2011-10-28 |
2022-05-27 |
瑞泽恩制药公司 |
T细胞受体基因修饰小鼠
|
|
SMT202200205T1
(it)
|
2011-10-28 |
2022-07-21 |
Regeneron Pharma |
Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii
|
|
CN108866101A
(zh)
|
2011-10-28 |
2018-11-23 |
瑞泽恩制药公司 |
人源化il-6和il-6受体
|
|
SMT201900478T1
(it)
|
2011-10-28 |
2019-09-09 |
Regeneron Pharma |
Topi con complesso maggiore di istocompatibilita' geneticamente modificati
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
BR112014010580B1
(pt)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
|
|
US9120662B2
(en)
|
2011-11-14 |
2015-09-01 |
Susan A. Thomson |
Gathering and dispensing scoop with gate valve
|
|
US9547499B2
(en)
|
2011-12-09 |
2017-01-17 |
Microsoft Technology Licensing, Llc |
Device configuration with cached pre-assembled driver state
|
|
EP3539374A1
(en)
|
2012-03-16 |
2019-09-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
EP2825036B1
(en)
|
2012-03-16 |
2018-05-02 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
|
WO2013138681A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
JP5920830B2
(ja)
|
2012-09-28 |
2016-05-18 |
シスメックス株式会社 |
試料調製装置および細胞分析装置
|
|
PT2931030T
(pt)
|
2012-12-14 |
2020-08-03 |
Open Monoclonal Tech Inc |
Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
|
|
CN111484999B
(zh)
|
2013-02-20 |
2024-10-25 |
瑞泽恩制药公司 |
人源化的t细胞共受体的小鼠
|
|
MY178882A
(en)
|
2013-02-20 |
2020-10-21 |
Regeneron Pharma |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
EP3699190B9
(en)
|
2013-02-22 |
2023-10-04 |
Regeneron Pharmaceuticals, Inc. |
Murine cell expressing humanized major histocompatibility complex
|
|
DK3456831T3
(da)
|
2013-04-16 |
2021-09-06 |
Regeneron Pharma |
Målrettet modifikation af rottegenom
|
|
US9783618B2
(en)
*
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
KR102170502B1
(ko)
|
2013-12-11 |
2020-10-28 |
리제너론 파마슈티칼스 인코포레이티드 |
게놈의 표적화된 변형을 위한 방법 및 조성물
|
|
AU2015231025A1
(en)
|
2014-03-21 |
2016-09-15 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
CA3124228C
(en)
|
2014-03-21 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
HRP20200529T1
(hr)
|
2014-06-06 |
2020-09-04 |
Regeneron Pharmaceuticals, Inc. |
Postupci i pripravci za modificiranje ciljnog lokusa
|
|
IL287519B2
(en)
*
|
2014-06-19 |
2024-01-01 |
Regeneron Pharma |
Non-human animals having a humanized programmed cell death 1 gene
|
|
ES2781323T3
(es)
|
2014-06-23 |
2020-09-01 |
Regeneron Pharma |
Montaje de ADN mediado por nucleasas
|
|
SI3161128T1
(sl)
|
2014-06-26 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe
|
|
JP2017529841A
(ja)
|
2014-09-19 |
2017-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ抗原受容体
|
|
EP4248744A3
(en)
|
2015-04-06 |
2023-12-27 |
Regeneron Pharmaceuticals, Inc. |
Humanized t cell mediated immune responses in non-human animals
|
|
KR102483193B1
(ko)
|
2016-06-03 |
2023-01-04 |
리제너론 파마슈티칼스 인코포레이티드 |
외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
|